v3.26.1
Share Options (Tables)
 6 Months Ended
Jun. 30, 2026
Share Options [Abstract]  
Schedule of Company’s Share Option Activity for Employees and Members of the Board of Directors

The following table presents the Company’s share option activity for employees and members of the Board of Directors of the Company under the Plan for the six month periods ended June 30, 2026 and 2025:

 

    Number of
Share
Options		     Weighted
Average
Exercise
Price		     Weighted
average
remaining
contractual
life		     Intrinsic
value		  
          $     (years)     $  
                         
Outstanding as of December 31, 2025     1,491,776       2.91       6.83       68  
Granted     128,400       1.73       -       -  
Exercised     -       -       -       -  
Cancelled     (62,380 )     -       -       -  
Outstanding as of June 30, 2026 (unaudited)     1,557,796       2.74       6.77       46.2  
Exercisable as of June 30, 2026 (unaudited)     977,392       2.46       5.69       46.2  

 

 

    Number of
Share
Options		     Weighted
Average
Exercise
Price		     Weighted
average
remaining
contractual
life		     Intrinsic
value		  
          $     (years)     $  
                         
Outstanding as of December 31, 2024     1,345,036       2.95       7.17       2,677  
Granted     161,000       2.87       -       -  
Exercised     (11,060 )     1.77       -       -  
Cancelled     (53,200 )     3.25       -       -  
Outstanding as of June 30, 2025 (unaudited)     1,441,776       2.94       7.14       1,125  
Exercisable as of June 30, 2025 (unaudited)     689,274       2.20       4.98       860  
Schedule of Ranges of Exercise Prices

The outstanding share options as of June 30, 2026 have been separated into ranges of exercise prices, as follows:

 

Exercise price   Share options
outstanding
as of
June 30,
2026		     Weighted
average
remaining
contractual
term		     Share options
exercisable
as of
June 30,
2026		     Weighted
average
remaining
contractual
term		  
    Unaudited  
          (years)           (years)  
                         
-     17,680       0.70       17,680       0.70  
1.14     82,580       0.98       82,580       0.98  
1.48     50,000       7.21       34,375       7.21  
1.65     80,000       9.67       6,672       9.67  
1.74     12,800       6.80       9,600       6.80  
1.83     552,334       5.24       517,674       5.16  
1.84     18,400       9.90       -       -  
1.88     30,000       9.91       -       -  
1.94     8,800       9.47       -       -  
2.30     10,400       8.82       2,600       8.82  
2.40     10,000       8.82       2,500       8.82  
2.43     8,800       8.75       2,750       8.75  
2.87     39,800       9.22       2,850       9.22  
2.97     92,000       8.47       32,475       8.46  
2.98     99,400       8.99       24,848       8.99  
3.14     5,000       9.05       936       9.05  
3.20     5,002       5.15       5,002       5.15  
3.59     28,800       8.24       12,600       8.24  
4.00     76,000       6.68       76,000       6.68  
4.96     300,000       8.07       131,250       8.07  
5.02     30,000       7.99       15,000       7.99  
      1,557,796               977,392          
Schedule of Assumptions Used to Estimate the Fair Values of the Options Granted

The following table presents the assumptions used to estimate the fair values of the share options granted in the reported periods presented:

 

    Six-month period ended
June 30,		  
    2026     2025  
             
Volatility (%)     63.47%-64.14 %     60.51%-61.52 %
Risk-free interest rate (%)     4.2%-4.3 %     3.9%-4.5 %
Dividend yield (%)     -       -  
Expected life (years)     6.25       6.25  
Exercise price ($)     1.65-1.88       2.30-4.00  
Share price ($)     1.65-1.97       2.40-4.00  
Schedule of Total Compensation Cost

The total compensation cost related to all of the Company’s equity-based awards recognized in profit and loss during the six month periods ended June 30, 2026 and 2025 was comprised as follows:

 

    Six-month period ended
June 30,		  
    2026     2025  
    Unaudited  
             
Research and development   $ 128     $ 137  
Sales and marketing     132       13  
General and administrative     55       177  
    $ 315     $ 327